All In Biotech

Drug Trial Radar · NCT06971614

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

An Open-Label, International, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Intravesical T3011 Injection in Participants With BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) or BCG-Exposed, Chemotherapy-Unresponsive Intermediate /High-Risk NMIBC

Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Jun 9, 2025

Primary completion

Dec 31, 2028

Study completion May 31, 2029

Sponsor

Lead sponsor
ImmVira Pharma Co. LtdIndustry
Sponsor type
Industry
First posted
May 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or BCG-exposed, chemotherapy-unresponsive intermediate/high-risk NMIBC.

Conditions

  • Nonmuscle-invasive Bladder Cancer

Interventions

  • T3011Biological

    T3011 will be administered at a dose of 1x10\^10 PFU intravesically.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Response Rate in patients with CISTime frame: 3,6,12 months time point from the date of the first dose of T3011
  2. Recurrence Free Survival Rate in patients with Ta/T1 (without CIS)Time frame: 3,6,12 months time point from the date of the first dose of T3011
  3. Incidence rates of Grade ≥3 treatment-related adverse events (TRAEs)Time frame: 24 months
  4. Incidence rates of TRAEs leading to treatment discontinuation, dose modification or treatment interruption.Time frame: 24 months

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • East Valley Urology Center

    Queen Creek, Arizona · Recruiting

  • Tower Urology

    Los Angeles, California · Recruiting

  • Advent Health Medical Group Urology

    Orlando, Florida · Recruiting

  • Florida Urology Partners, LLP

    Tampa, Florida · Recruiting

  • Rutgers Cancer Institute

    New Brunswick, New Jersey · Recruiting

  • University of Cincinnati Medical Center

    Cincinnati, Ohio · Recruiting

  • Helios Clinical Research

    Middleburg Heights, Ohio · Recruiting

  • Allegheny Health Network

    Pittsburgh, Pennsylvania · Recruiting

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.